CLARA Interview Transcript
Generated: 06/11/2025, 03:30:45 PM
Original File: interview-20250611_153045-Board Advisory Feedback.mp4
Report ID: client-006
Company: BioPharma Solutions

==================================================

Thank you for taking the time to speak with me today. This conversation is confidential and will help us improve our future engagements. To recap, we worked with BioPharma Solutions on board effectiveness assessment and ceo succession planning. We understand you've selected Egon Zehnder for this engagement.

Could you share the top factors that influenced your decision? The key factors were Pharmaceutical board relationships, regulatory expertise, proven pharma succession experience. The competitor demonstrated superior capabilities in these areas, which were critical for our success.

How did our proposal compare to Egon Zehnder's in terms of pricing, service capability, and product fit? The comparison showed gaps in our offering, particularly in Limited pharma board connections, less regulatory knowledge, generic succession planning. While some aspects were competitive, the competitor's strengths in Extensive pharma board network, deep regulatory expertise, specialized pharma succession methodology were decisive.

Were there any specific gaps where our offering didn't meet your expectations? The main gaps were Limited pharma board connections, less regulatory knowledge, generic succession planning. These gaps were significant because they directly impacted our ability to achieve our objectives.

What aspects of Egon Zehnder's offering stood out to your team? Their key strengths were Extensive pharma board network, deep regulatory expertise, specialized pharma succession methodology. These capabilities directly addressed our most critical needs and concerns.

Did Egon Zehnder offer anything innovative that tipped the scales? Yes, Regulatory leadership assessment that evaluated board members' ability to navigate FDA and international regulatory challenges. This innovation provided significant value that we couldn't get elsewhere.

How would you describe your experience working with our team? Professional and insightful, good chemistry with our board. Robert Kim and the team were professional and engaged throughout the process.

Were there moments where our approach stood out positively or negatively? Board assessment methodology was comprehensive, but lacked pharma-specific elements. While there were positive aspects, some areas needed improvement.

How was the chemistry and collaboration between our teams? The chemistry and collaboration were positive throughout the engagement. Both teams worked well together and maintained professional relationships.

Despite this decision, do you see opportunities to work together in the future? Yes, for general board advisory or if we develop pharma expertise. There are areas where your capabilities would be a good fit for our needs.

What would you need to see from us to feel more confident choosing us for a future project? Pharmaceutical industry relationships, regulatory expertise, pharma-specific board assessment tools. These improvements would make you much more competitive for similar engagements.

Thank you for your time and candid feedback. This has been extremely valuable for our team.